The Alberta Psychiatric Association requires disclosure of the existence of ANY AND ALL financial interest(s) or other affiliation(s) a presenter has with commercial supporter(s) of these educational activities, and/or with manufacturer(s) of ANY AND ALL commercial product(s) and/or provider(s) of ANY AND ALL commercial services discussed in the scientific program. The existence of such relationships does not necessarily constitute a conflict of interest, but the prospective audience must be informed of the presenter’s affiliation with every commercial sponsor by way of an acknowledgement in program.
This policy is intended to openly identify any potential conflict(s) so that members of the audience in an educational activity are able to form their own opinions about the presentation. A reasonable test to guide decisions about what to disclose is whether any particular affiliation could cause embarrassment to the individual or institution involved or lead to questions about the presenter’s motives if such affiliation(s) were made known to the general public.
The following presenters have indicated a financial interest in other affiliation with a commercial supporter of the sessions and/or with the manufacturer(s) of commercial product and/or provider of commercial service(s):
|PJ Cowen||Ebselen, University of Oxford|
|Morgan Glass||Thomas J. Raedler||AbbVie / Allergan, Boehringer Ingelheim, Janssen, Lundbeck, Otsuka, Purdue, Sunovion, SyneuRx International, Teva|
|Justine Greer||Alberta Health Services, PARA Resident Wellness Initiative Grant|
|Olivia Guerra||Alberta Health Services, PARA Resident Wellness Initiative Grant|
JE Hallak is co-inventor (Mechoulam R, JC, Guimaraes FS, AZ, Hallak JE, Breuer A) of the patent “Fluorinated CBD compounds, compositions and uses thereof. Pub. No.: WO/2014/108899. International Application No.: PCT/IL2014/050023” Def. US no. Reg. 62193296; 29/07/2015; INPI on 19/08/2015 (BR1120150164927). The University of São Paulo has licensed the patent to Phytecs Pharm (USP Resolution No. 15.1.130002.1.1). The University of São Paulo has an agreement with Prati-Donaduzzi (Toledo, Brazil) to “develop a pharmaceutical product containing synthetic cannabidiol and prove its safety and therapeutic efficacy in the treatment of epilepsy, schizophrenia, Parkinson’s disease, and anxiety disorders”
|Trevor W. Robbins||
Arcadia, Cambridge Cognition, Cassava Science, Dohme, Elsevier, GlaxoSmithKline, Greenfield Bioventures, Heptares, Lundbeck, Merck Sharp, Shionogi, Springer Nature (editorial honoraria), Takeda.
Royalties from Cambridge Cognition.
|Jonathan Rogers||Promentis Pharmaceuticals, Wellcome Trust Clinical Training Fellowship|